|View printer-friendly version|
Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
“We are pleased to formalize a new phase of our partnership with OHM Oncology, which originated in late 2015 from the work performed by its R&D partner LAXAI Life Sciences (LAXAI) on a discovery stage program,” said
“Aptose has proven to be an excellent integrated drug discovery partner for LAXAI and this agreement is the outgrowth of our collaboration started in 2015,” said
Under the agreement, Aptose will receive a nominal upfront cash payment and is eligible to receive up to
About OHM Oncology and LAXAI Life Sciences
LAXAI Life Sciences was established in 2007 with a vision to innovate and accelerate the drug discovery campaigns of global pharmaceutical companies, and OHM Oncology (OHM) was formed in 2016 to advance the clinical development of compelling oncology molecules. The goal of LAXAI is to provide intelligent solutions to global pharmaceutical and biotechnological companies by providing high quality services with accelerated timelines. LAXAI provides a one-stop service for pharmaceutical and biotechnology companies around the globe to accelerate drug discovery programs. LAXAI’s current client base includes Biopharmaceutical, Agrochemical and Specialty Chemical Companies in Europe and the US.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to the exclusive global license agreement between Aptose and OHM/LALS, the potential clinical development of APL-581 and its therapeutic effects, potential payments that may be received under the license agreement as well as statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of clinical trials; changing market conditions; potential loss of API; inability of new manufacturers to produce acceptable batches of cGMP clinical supplies in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the
For further information, please contact:
Source: Aptose Biosciences, Inc.